iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Biocon Biologics announces integration of Viatris’ Europe biosimilar business

1 Dec 2023 , 10:48 AM

Biocon Biologics, a Biocon subsidiary, stated on Thursday that the integration of Viatris’ biosimilars business in 31 European nations was completed.

Following the acquisition of substantially all of Viatris’ global biosimilar business in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, the company said in a release that the full transition of Viatris’ biosimilars operations to Biocon Biologics Ltd in Europe represents another significant milestone.

Biocon Biologics has seven biosimilars in its portfolio in Europe, including Insulin Aspart, Bevacizumab, Adalimumab, Pegfilgrastim, Insulin Glargine, Trastuzumab, and Etanercept.

The integration of Viatris’ biosimilar business in Europe ahead of schedule is another significant milestone for Biocon Biologics in our journey to become a global biosimilars leader, said Shreehas Tambe, CEO & MD, Biocon Biologics.

At around 10.44 AM, Biocon was trading 1.34% higher at Rs 241.50, against the previous close of Rs 238.30 on NSE. 

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Biocon
  • Biocon Biologics
  • Biocon Europe
  • Biocon news
  • Biocon Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

SBI Card Q4 Profit Slips 20%
25 Apr 2025|11:17 PM
HUL Q4 Net Profit Rises to ₹2,493 Crore
25 Apr 2025|10:59 PM
Sensex and Nifty in Red on April 25, 2025
25 Apr 2025|02:08 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.